ESC 365 - The benefits of icosapent ethyl in addressing residual risk: what is the evidence?

Open Access

The benefits of icosapent ethyl in addressing residual risk: what is the evidence?

Session: New paradigms in the prevention of ASCVD: the role of EPA and triglycerides

Topic: Lipids

Speaker: Professor L. Tokgozoglu (Ankara, TR)

Sponsored by PACE-CME, supported by an educational grant from Amarin

Event: ESC Preventive Cardiology 2023

Congress Presentation

Add to my library

About the speaker

Professor Lale Tokgozoglu

Hacettepe University, Ankara (Türkiye)

44 presentations

8 followers

4 more presentations in this session

Introduction

Speaker: Professor F. Visseren (Utrecht, NL)

Reassessing the role of triglyceride-related residual risk based on recent evidence

Speaker: Professor R. Hobbs (Oxford, GB)

Integrating icosapent ethyl in preventive strategies: practical guidance

Speaker: Professor V. Aboyans (Limoges, FR)

Discussion

Speaker: Professor F. Visseren (Utrecht, NL)

Access the full session

New paradigms in the prevention of ASCVD: the role of EPA and triglycerides

Speakers: Professor L. Tokgozoglu, Professor F. Visseren, Professor R. Hobbs, Professor V. Aboyans, Professor F. Visseren

About the event

ESC Preventive Cardiology 2023

13 April - 15 April 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources